Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

被引：80

作者：

Azorsa, David O. ^{[1
]}

Gonzales, Irma M. ^{[1
]}

Basu, Gargi D. ^{[1
]}

Choudhary, Ashish ^{[1
]}

Arora, Shilpi ^{[1
]}

Bisanz, Kristen M. ^{[1
]}

Kiefer, Jeffrey A. ^{[1
]}

Henderson, Meredith C. ^{[1
]}

Trent, Jeffrey M. ^{[2
]}

Von Hoff, Daniel D. ^{[3
]}

Mousses, Spyro ^{[1
]}

机构：

[1] Translat Genom Res Inst, Pharmaceut Genom Div, Scottsdale, AZ 85259 USA

[2] Translat Genom Res Inst, Genet Basis Human Dis Div, Phoenix, AZ 85004 USA

[3] Translat Genom Res Inst, Clin Translat Res Div, Phoenix, AZ 85004 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2009年 / 7卷

关键词：

DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; BREAST-CANCER; TUMOR-GROWTH; CHK1; INTERFERENCE; INHIBITION; KINASES; ABROGATION; SURVIVAL;

D O I：

10.1186/1479-5876-7-43

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers. It affects 230,000 individuals worldwide, has a very high mortality rate, and remains one of the most challenging malignancies to treat successfully. Treatment with gemcitabine, the most widely used chemotherapeutic against pancreatic cancer, is not curative and resistance may occur. Combinations of gemcitabine with other chemotherapeutic drugs or biological agents have resulted in limited improvement. Methods: In order to improve gemcitabine response in pancreatic cancer cells, we utilized a synthetic lethal RNAi screen targeting 572 known kinases to identify genes that when silenced would sensitize pancreatic cancer cells to gemcitabine. Results: Results from the RNAi screens identified several genes that, when silenced, potentiated the growth inhibitory effects of gemcitabine in pancreatic cancer cells. The greatest potentiation was shown by siRNA targeting checkpoint kinase 1 (CHK1). Validation of the screening results was performed in MIA PaCa-2 and BxPC3 pancreatic cancer cells by examining the dose response of gemcitabine treatment in the presence of either CHK1 or CHK2 siRNA. These results showed a three to ten-fold decrease in the EC50 for CHK1 siRNA-treated cells versus control siRNA-treated cells while treatment with CHK2 siRNA resulted in no change compared to controls. CHK1 was further targeted with specific small molecule inhibitors SB 218078 and PD 407824 in combination with gemcitabine. Results showed that treatment of MIA PaCa-2 cells with either of the CHK1 inhibitors SB 218078 or PD 407824 led to sensitization of the pancreatic cancer cells to gemcitabine. Conclusion: These findings demonstrate the effectiveness of synthetic lethal RNAi screening as a tool for identifying sensitizing targets to chemotherapeutic agents. These results also indicate that CHK1 could serve as a putative therapeutic target for sensitizing pancreatic cancer cells to gemcitabine.

引用

页数：12

共 53 条

[1] Cell cycle checkpoint signaling through the ATM and ATR kinases [J].

Abraham, RT .

GENES & DEVELOPMENT, 2001, 15 (17) :2177-2196

[2] Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP on chip [J].

Arora, Shilpi ;

Wang, Yipeng ;

Jia, Zhenyu ;

Vardar-Sengul, Saynur ;

Munawar, Ayla ;

Doctor, Kutbuddin S. ;

Birrer, Michael ;

McClelland, Michael ;

Adamson, Eileen ;

Mercola, Dan .

GENOME BIOLOGY, 2008, 9 (11)

[3] Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening [J].

Aza-Blanc, P ;

Cooper, CL ;

Wagner, K ;

Batalov, S ;

Deveraux, QL ;

Cooke, MP .

MOLECULAR CELL, 2003, 12 (03) :627-637

[4] Association of steroid receptor coactivator AIB1 with estrogen receptor-α in breast cancer cells [J].

Azorsa, DO ;

Cunliffe, HE ;

Meltzer, PS .

BREAST CANCER RESEARCH AND TREATMENT, 2001, 70 (02) :89-101

[5]

AZORSA DOM, 2004, LETT PEPTIDE RES, V10, P361

[6] Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors:: A pediatric oncology experimental therapeutics investigators consortium study [J].

Bagatell, Rochelle ;

Gore, Lia ;

Egorin, Merrill J. ;

Ho, Richard ;

Heller, Glenn ;

Boucher, Nichole ;

Zuhowski, Eleanor G. ;

Whitlock, James A. ;

Hunger, Stephen P. ;

Narendran, Aru ;

Katzenstein, Howard M. ;

Arceci, Robert J. ;

Boklan, Jessica ;

Herzog, Cynthia E. ;

Whitesell, Luke ;

Ivy, S. Percy ;

Trippett, Tanya M. .

CLINICAL CANCER RESEARCH, 2007, 13 (06) :1783-1788

[7] Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions [J].

Bartz, Steven R. ;

Zhang, Zhan ;

Burchard, Julja ;

Imakura, Maki ;

Martin, Melissa ;

Palmieri, Anthony ;

Needham, Rachel ;

Guo, Jie ;

Gordon, Marcia ;

Chung, Namjin ;

Warrener, Paul ;

Jackson, Aimee L. ;

Carleton, Michael ;

Oatley, Melissa ;

Locco, Louis ;

Santini, Francesca ;

Smith, Todd ;

Kunapuli, Priya ;

Ferrer, Marc ;

Strulovici, Berta ;

Friend, Stephen H. ;

Linsley, Peter S. .

MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (24) :9377-9386

[8] Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer [J].

Bepler, Gerold ;

Sommers, K. Eric ;

Cantor, Alan ;

Li, Xueli ;

Sharma, Anupama ;

Williams, Charles ;

Chiappori, Alberto ;

Haura, Eric ;

Antonia, Scott ;

Tanvetyanon, Tawee ;

Simon, George ;

Obasaju, Coleman ;

Robinson, Lary A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1112-1118

[9] Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 [J].

Blasina, Alessandra ;

Hallin, Jill ;

Chen, Enhong ;

Arango, Maria Elena ;

Kraynov, Eugenia ;

Grant, Stephan ;

Ninkovic, Sacha ;

Chen, Ping ;

Nichols, Tim ;

O'Connor, Patrick ;

Anderes, Kenna .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) :2394-2404

[10] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

← 1 2 3 4 5 6 →